article thumbnail

RNA-based immunotherapy eradicates melanoma tumours

Drug Discovery World

This immunosuppressive environment that impedes activation of cancer-killing T cells allows tumours to grow, according to the researchers. The researchers named their approach CATCH. As part of the regimen, the researchers used new types of lipid nanoparticles to deliver two mRNA therapeutics.

RNA 52
article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

Another area where we tend to see problems is in encapsulation efficiency,” says Andrew Kondratowicz, Bioassay Team Lead, Precision NanoSystems. The bioassays are the canary in the coal mine of how well your process development is going. Outlook The era of mRNA-based genomic medicines is on the horizon. Where is your payload?

Bioassay 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evaluating methods targeting Protein-Protein Interactions

pharmaphorum

It is a popular method in systems biology, requiring fewer compounds to be screened in bioassays, reducing time and cost. A recent clinical research paper highlights the importance of targeting of PPIs in stem cells of cancer. This innovative method now brings technology closer to developing genome-wide PPI networks.

Protein 125
article thumbnail

Reimagining cell engineering with picodroplet microfluidic technology

Drug Discovery World

Cell engineering is bringing life science into a new era of biotherapeutic discovery and development, disease modelling, and synthetic biology research. Not only does this fully integrated workflow accelerate cell engineering timelines and reduce overall costs, it gives a user-friendly, flexible and controlled option for researchers.

article thumbnail

Can artificial intelligence help craft new medicines?

Drug Discovery World

Here, new bioassay technologies helped testing, but more definite answers were required. Expression patterns, proteomic profiles, bioassay results, and structures could now be captured en masse in normal and disease conditions. Thus, there was a dire need for new and effective drug targets.